4,685 Incyte Corporation $INCY Shares Bought by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. increased its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 63.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,079 shares of the biopharmaceutical company’s stock after buying an additional 4,685 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Incyte were worth $1,466,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Incyte in the second quarter worth about $2,044,189,000. Wellington Management Group LLP boosted its position in shares of Incyte by 9.5% in the second quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock valued at $405,321,000 after acquiring an additional 309,385 shares during the period. Dimensional Fund Advisors LP grew its stake in Incyte by 10.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after acquiring an additional 187,354 shares in the last quarter. Legal & General Group Plc purchased a new position in Incyte during the second quarter valued at approximately $182,054,000. Finally, Pacer Advisors Inc. increased its holdings in Incyte by 2.2% during the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock worth $163,869,000 after acquiring an additional 37,790 shares during the period. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Sanford C. Bernstein increased their target price on shares of Incyte from $104.00 to $108.00 and gave the stock a “market perform” rating in a research note on Monday, November 2nd. Piper Sandler upped their price target on shares of Incyte from $110.00 to $130.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Citigroup reaffirmed a “buy” rating on shares of Incyte in a report on Monday, August 3rd. UBS Group set a $152.00 target price on Incyte in a research report on Friday, October 30th. Finally, Canaccord Genuity Group began coverage on Incyte in a research note on Thursday, August 20th. They issued a “buy” rating and a $152.00 target price on the stock. Eleven research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $134.38.

Get Our Latest Research Report on Incyte

Insider Buying and Selling

In other news, insider Pablo Cagnoni sold 2,642 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider owned 183,200 shares of the company’s stock, valued at approximately $20,648,472. The trade was a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Heeson sold 10,694 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $120.82, for a total value of $1,292,049.08. Following the completion of the sale, the executive vice president owned 26,884 shares of the company’s stock, valued at $3,248,124.88. The trade was a 28.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 254,139 shares of company stock worth $30,098,844 in the last ninety days. Corporate insiders own 16.20% of the company’s stock.

Incyte Stock Performance

Shares of NASDAQ:INCY opened at $114.63 on Friday. The firm has a market capitalization of $23.37 billion, a PE ratio of 60.97, a price-to-earnings-growth ratio of 4.09 and a beta of 0.78. The firm has a fifty day moving average of $118.49 and a 200 day moving average of $109.37. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. Incyte’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period last year, the firm posted $2.26 EPS. On average, sell-side analysts forecast that Incyte Corporation will post 2.29 EPS for the current fiscal year.

About Incyte

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

See Also

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.